CONTACT US
Home / Blog/Client Alert: DOJ Reschedules FDA-Approved and State-Licensed Medical Marijuana to Schedule III

Client Alert: DOJ Reschedules FDA-Approved and State-Licensed Medical Marijuana to Schedule III

April 24, 2026

CLIENT ALERT

DOJ Reschedules FDA-Approved and State-Licensed Medical Marijuana to Schedule III

What It Could Mean for Tax, Enforcement, Banking, and Deal Activity

By Attorney Eric I. Collins

Overview

On April 22, 2026, Acting Attorney General Todd Blanche, acting through the Drug Enforcement Administration (“DEA”), issued a final order (the “Order”) transferring two categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”): (i) FDA-approved drug products containing marijuana, and (ii) marijuana subject to a qualifying state-issued medical marijuana license. The Order is effective immediately and marks the most significant change in the federal legal status of marijuana in more than fifty years.

The Order implements President Trump’s December 18, 2025 Executive Order directing the Department of Justice to expedite marijuana rescheduling, and relies on a streamlined CSA pathway tied to U.S. obligations under international drug control treaties. Three points should be front of mind for clients:

  • Recreational (adult-use) marijuana remains a Schedule I controlled substance. The Order does not legalize recreational cannabis at the federal level, and operators in the adult-use market continue to face the full range of federal administrative, civil, and criminal sanctions.
  • Hemp-derived and synthetic THC products are not covered. The Order does not alter the federal status of hemp-derived cannabinoid products (including Delta-8 and other hemp-derived THC beverages and edibles) or synthetically derived THC.
  • A broader rescheduling proceeding is pending. DEA has withdrawn the prior notice of hearing associated with the May 2024 proposed rule and terminated those proceedings. A new, expedited administrative hearing concerning the broader rescheduling of all marijuana to Schedule III is scheduled to commence June 29, 2026, with accelerated deadlines.

 

Key Legal Implications

1. IRC § 280E and Federal Tax Treatment

Section 280E of the Internal Revenue Code disallows deductions and credits for any business “trafficking” in Schedule I or Schedule II controlled substances. Because the Order moves covered medical marijuana to Schedule III, state-licensed medical marijuana operators should, prospectively, no longer be subject to § 280E’s deduction disallowance. The Order itself acknowledges this consequence and notes that the Acting Attorney General has encouraged the Secretary of the Treasury to consider retrospective relief for prior taxable years in which a licensee operated under a qualifying state license.

Several important caveats apply:

  • The Order expressly disclaims any determination regarding federal tax liability. Taxpayers should not claim § 280E relief without coordinated guidance from tax counsel, and we expect IRS guidance (likely a Notice, Revenue Procedure, or FAQs) in the coming months.
  • Relief is tied to state medical license status. Vertically integrated multi-state operators (“MSOs”) with mixed medical/adult-use footprints will need to allocate revenues, COGS, and operating expenses between rescheduled and non-rescheduled activities. Operators should expect the IRS to scrutinize allocations aggressively.
  • Retrospective relief is not guaranteed. Any refund claims for open tax years (generally the last three) will likely require Treasury guidance, protective refund claims, and, in some cases, litigation. Operators with pending § 280E disputes, open examinations, or unresolved Tax Court cases should reassess strategy immediately.
  • Uniform capitalization, inventory accounting, and Section 471 positions that were developed specifically to mitigate § 280E exposure should be revisited.

 

2. Federal Criminal Liability and Enforcement

Schedule III status reduces, but does not eliminate, federal criminal exposure for covered activities, and it does not alter the legal status of activities outside the Order’s scope.

  • Manufacturing, distribution, and dispensing of Schedule III marijuana products remain federal crimes absent proper DEA registration and compliance with Schedule III controls (including security, recordkeeping, labeling, disposal, and reporting obligations). State licensure alone will not be sufficient for federal compliance.  The details concerning the state/federal interplay will hopefully be fleshed out in the June rulemaking.
  • Adult-use operations remain Schedule I activity, and federal prohibitions on cultivation, manufacture, distribution, and possession for recreational purposes are unchanged. The federal-state conflict that has defined the industry for more than a decade persists.
  • Congressional appropriations protections (e.g., Rohrabacher-Farr / the current medical marijuana funding rider) remain operative for covered medical operators and continue to constrain DOJ enforcement, but those protections are annual and subject to legislative change.
  • The Order does not affect existing convictions, sentences, or pending prosecutions. Clients with legacy federal exposure should not interpret the Order as a pardon, expungement, or safe harbor.

 

3. Banking, Financing, and Capital Markets

Rescheduling of covered medical marijuana to Schedule III meaningfully improves — but does not fully resolve — capital access challenges.

  • Depository institutions should anticipate revised guidance from FinCEN and federal banking regulators. The existing 2014 FinCEN guidance and associated marijuana-related SAR regime will likely be modified. Lenders with cannabis exposure should expect to revisit KYC, Bank Secrecy Act, and anti-money laundering programs, and to reconsider enterprise-wide risk frameworks that previously treated all cannabis as Schedule I.
  • Capital markets access should expand at the margins. U.S. cannabis operators should, over time, gain broader access to commercial lending, syndicated credit facilities, and potentially mainstream equity markets. Major U.S. exchange listings (NYSE, Nasdaq) remain subject to exchange-level determinations and SEC guidance, which have not yet been issued.
  • Existing credit documentation in cannabis transactions — often heavily negotiated around CSA compliance, forfeiture risk, and change-of-control triggers — should be reviewed. Material adverse change, illegality, representation and warranty, and regulatory change clauses may be triggered or rendered moot by the Order.  Debt covenants may need re‑engineering as well (e.g., moving from “tax burn” assumptions to conventional EBITDA‑based leverage frameworks).
  • Insurance markets (D&O, product liability, property, and cyber) should, hopefully, over time, offer broader coverage and improved pricing for covered operators, though underwriters will move cautiously pending further regulatory clarity.

 

4. M&A Activity and Corporate Structuring

The Order is likely to accelerate transactional activity and to reshape deal structures and diligence in several ways:

  • Valuation. Removal of § 280E from the effective tax cost structure of state-licensed medical operations will drive material EBITDA and free-cash-flow re-rating. Buyers and sellers should expect a recalibration of multiples and should revisit earn-out, working capital, and tax-benefit-sharing mechanics in signed but unclosed deals.
  • Deal structuring. Legacy “up-C,” multi-tier, and non-plant-touching management-services structures were often designed to mitigate § 280E exposure, preserve public-market listings, or insulate institutional investors from Schedule I risk. Many of those structures will remain useful (particularly where adult-use assets are in the mix), but others can now be simplified.
  • Diligence. Tax diligence should now cover protective § 280E refund positions, uniform capitalization and inventory method changes, and allocation between medical and adult-use lines. Depending on rulemaking, regulatory diligence could include DEA registration status, Schedule III compliance readiness, and exposure on non-covered product lines (including hemp-derived THC and synthetic cannabinoids).
  • Strategic activity. We expect increased interest from pharmaceutical companies, consumer health companies, and institutional private equity that previously avoided the sector. Cross-border transactions (particularly involving Canadian LPs) and pharmaceutical partnerships could accelerate.

 

5. Branding and IP

Rescheduling could be meaningful for cannabis-adjacent branding and IP strategies, particularly for businesses that have historically relied on state trademark regimes and contract-based brand protection.

  • Trademarks.  Despite rescheduling, trademark rights are built around the concept of “use in commerce”, meaning interstate commerce which is lawfully regulated by Congress.  While moving marijuana from Schedule I to Schedule III would be a significant change in federal drug policy, DEA has stated that, even if transferred to Schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to CSA criminal prohibitions. For many operators, the practical trademark question therefore becomes whether the relevant goods/services would be viewed as “lawful” for federal trademark purposes in the post-rescheduling landscape, particularly if products are not manufactured and distributed in a manner that satisfies applicable federal requirements
  • Patents: On the patent side, rescheduling does not change the basic statutory standard that patents may be obtained for “any new and useful” process, machine, manufacture, or composition of matter, subject to the Patent Act’s conditions and requirement.  The more immediate business implication is likely to be in diligence and valuation: investors and strategic acquirers may reassess the commercialization pathways, regulatory risk, and enforceability/monetization of cannabis-related R&D and formulation portfolios as the federal framework evolves.

 

Open Questions and Areas to Monitor

Numerous issues remain unresolved. Clients should monitor developments in the following areas over the coming weeks and months:

  • IRS and Treasury guidance on § 280E applicability, retrospective relief mechanics, inventory method changes, and protective refund procedures.
  • DEA implementation guidance, including registration pathways for state-licensed medical operators, Schedule III compliance expectations, and interaction with state regulatory regimes.
  • FinCEN and federal banking regulator guidance on depository services, lending, and BSA/AML obligations for cannabis customers.
  • SEC and exchange guidance on U.S. listings and capital-raising activity by plant-touching operators.
  • The June 29, 2026 DEA administrative hearing on broader rescheduling of all marijuana (including adult-use). The outcome and timing of any resulting final rule will determine the scope of § 280E relief and federal decriminalization for adult-use operators.
  • State regulatory responses, including whether states modify licensing categories, tax structures, or reciprocity frameworks in response to federal rescheduling.
  • Hemp-derived THC, which remains outside the Order and is the subject to a definitional change in the 2026 Farm Bill scheduled to take effect of active Congressional debate in connection with the next Farm Bill on November 12, 2026.
  • Litigation, including expected challenges by industry participants, state attorneys general, and anti-legalization groups to the scope and procedure of the Order.

 

What This Means for You

For clients considering or executing transactions, capital raises, or restructurings in the near term, we recommend the following practical steps:

  • Cannabis operators should (i) inventory current and prior-year § 280E exposure, (ii) consider protective refund claims for open tax years, (iii) assess Schedule III registration and compliance readiness, (iv) reassess allocations between medical and adult-use lines of business, and (v) review existing credit, lease, and commercial agreements for change-in-law, regulatory-approval, and MAC triggers.
  • Buyers and investors (including private equity and strategic acquirers) should revisit valuation models, diligence checklists, and deal documentation to reflect the revised tax and regulatory environment, and should consider whether deal structures designed around Schedule I status can now be simplified.
  • Clients with pending transactions signed but not yet closed should promptly evaluate whether the Order constitutes a “change in law,” triggers any regulatory approval or closing condition, or affects pricing, earn-outs, or tax-benefit-sharing arrangements.
  • Employers should note that while other states including our neighboring states in New England have liberal cannabis laws, New Hampshire has only legalized medical marijuana and while there are bills pending in the state legislature to legalize recreational marijuana passage isn’t certain and Governor Ayotte has said that the federal rescheduling won’t change New Hampshire law.

 

In all cases, we caution against acting on the Order in isolation. Implementation will be shaped by forthcoming IRS, DEA, FinCEN, SEC, and FDA guidance, and by the outcome of the broader rescheduling hearing. Positions taken now should be designed to preserve flexibility as that guidance emerges.

Sheehan Phinney’s Cannabis Practice Group

If you have questions about how potential Schedule III rescheduling may affect your tax posture (including § 280E planning), enforcement exposure, banking relationships, or pending/anticipated M&A and capital markets activity, please contact any member of our Cannabis Practice Group to discuss transaction structuring, diligence, and risk allocation strategies tailored to your business and timeline.

This article is intended to serve as a summary of the issues outlined herein. While it may include some general guidance, it is not intended as, nor is it a substitute for, legal advice. The rescheduling of marijuana is a rapidly evolving area of federal law, and the legal effects of the April 22, 2026 Order will depend on forthcoming guidance from the IRS, DEA, FDA, FinCEN, SEC, and other federal agencies.